The global diabetes management app market is forecasted to grow from $1.71 billion in 2025 to $15.53 billion by 2035, driven by automation, AI insights, and integrated care platforms, with North America leading expansion and Asia-Pacific emerging rapidly.
The diabetes management apps market is set to expand sharply over the next decade as software moves away from simple manual logbooks and towards connected care platforms, according to a new DataM Intelligence report. The firm values the market at $1.71 billion in 2025 and expects it to rise to $15.53 billion by 2035, a forecast that points to a much broader role for apps that can combine device data, coaching and clinical workflows.
That outlook is more aggressive than several other market estimates. Grand View Research said the sector was worth $1.9 billion in 2024 and projected compound annual growth of 8.5% through 2030, while Market.us placed the market at $2.1 billion in 2024 and forecast growth to $4.8 billion by 2034. Despite the differences in size and pace, the reports agree on the same direction: diabetes apps are becoming more closely tied to continuous glucose monitoring, AI-driven insights and remote care.
DataM Intelligence argues that the biggest shift is from user-entered records to automatic data capture and interpretation. The report says apps are increasingly judged by whether they reduce the burden of self-management and produce information that clinicians can actually use between visits. It also highlights predictive analytics, which it says accounted for 32% of application revenue in 2025, as a growing feature for spotting patterns, forecasting glucose changes and supporting personalized coaching.
Reimbursement is emerging as another decisive factor. According to DataM Intelligence, paid subscriptions and licensed programs made up 62% of diabetes app revenue in 2025, showing how employers, insurers, providers and public programs are shaping demand. The report also says home-based management accounted for 68% of global revenue last year, reflecting the reality that most diabetes decisions are made outside the clinic and need to be supported by apps that can keep patients engaged without adding unnecessary work.
The report’s company profiles suggest the market is consolidating around integrated care platforms rather than standalone consumer tools. It points to Glooko’s device-neutral data platform, Welldoc’s coaching and enterprise dashboards, Dexcom’s expansion beyond glucose sensing and Roche Diabetes Care’s mySugr ecosystem as examples of firms building software around connected devices and provider workflows. DataM Intelligence says North America held 42% of global revenue in 2025, while Asia-Pacific is expected to grow quickly as Android-first design, local language support and lower costs broaden access.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
